Amphastar Pharmaceuticals (AMPH) Free Cash Flow (2013 - 2026)

Amphastar Pharmaceuticals' Free Cash Flow history runs 14 years deep, the most recent figure standing at $43.7 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 56.74% year-over-year to $43.7 million; the TTM figure through Mar 2026 stood at $164.2 million (up 6.81% YoY), while the FY2025 annual figure was $148.4 million, down 13.91% from the prior year.
• Free Cash Flow was $43.7 million for Q1 2026 at Amphastar Pharmaceuticals, down from $51.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $71.2 million in Q2 2024 to a low of $4.0 million in Q2 2022.
• Historically, Free Cash Flow has averaged $34.9 million across 5 years, with a median of $36.8 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow sank 87.83% in 2022, then soared 933.73% in 2023.
• A 5-year view of Free Cash Flow shows it stood at $27.7 million in 2022, then plunged by 47.92% to $14.4 million in 2023, then gained by 15.19% to $16.6 million in 2024, then surged by 211.39% to $51.7 million in 2025, then slipped by 15.59% to $43.7 million in 2026.
• The last three Free Cash Flow figures came in at $43.7 million (Q1 2026), $51.7 million (Q4 2025), and $32.0 million (Q3 2025), per Business Quant data.